Back to test list

RUNX1/RUNX1T1 FISH

Also known as: t(8;21) FISH, AML1/ETO FISH

Test category:

Oncology - Leukaemia

Use of test

Purpose:

Fusion of the AML1 and ETO genes defines a specific AML subtype. These two genes are also known as RUNX1 and RNX1T1 (respectively). This gene fusion is the result of a chromosomal translocation: t(8;21)(q22;q22). Identification of this fusion has prognostic implications.

Utility:

Fusion of AML1 and ETO is associated with favourable prognosis in adults with AML

Ethical considerations:

This is an assay for non-heritable mutations. It does not raise issues of ethics or consent that are different from most other investigations ordered in the routine care of a patient.

Methodology:

Fluorescent in situ hybridisation (FISH) analysis, using probes designed to detect AML1-ETO gene fusion.

Requesting the test

Ordering:

This test is usually requested by a haematologist or oncologist.

Sample required:

0.5 mL bone marrow in transport media (or 10 mL blood in lithium heparin if blasts >10%).

To help ensure the quality of the test, a genetic test should be done with a dedicated sample whenever possible i.e. a sample collected specifically for that test rather than a sample that is used for multiple tests.

We recommend that the patient or another adult check the labelling of request forms and sample tubes.

Turnaround time:

2 business days.

Price:

This test has a Medicare rebate which, subject to the requirements of the Medicare descriptor being met, may cover all or part of the cost.

Rebate:

The Medicare details, including descriptor and schedule fee, are listed under MBS item 73314.

Click here for our billing policy.